Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StrykerMEX:SYK 90 EV-to-EBITDA is 15.77 as of Sep. 10, 2026, which is 39% below its 10-year median of 25.81. GuruFocus rates MEX:SYK with a GF Score™ of 90/100 and a GF Value™ of MXN7,233.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 516 Medical Devices & Instruments companies, Stryker ranks worse than 59.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stryker's enterprise value is MXN1,980,505 Mil.
Stryker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MXN125,565 Mil. Therefore, Stryker's EV-to-EBITDA for today is 15.77.
The historical rank and industry rank for Stryker's EV-to-EBITDA or its related term are showing as below:
MEX:SYK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.2 Med: 25.81 Max: 37.99
Current: 16.72
During the past 13 years, the highest EV-to-EBITDA of Stryker was 37.99. The lowest was 16.20. And the median was 25.81.
MEX:SYK's EV-to-EBITDA is ranked worse than 59.3% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.925
vs MEX:SYK: 16.72
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-10), Stryker's stock price is MXN4770.00.
Stryker's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was MXN172.426. Therefore, Stryker's PE Ratio (TTM) for today is 27.66.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stryker's share price for today is MXN4770.00.
Stryker's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN172.426.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Stryker's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Stryker's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stryker EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stryker's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stryker's EV-to-EBITDA falls into.
Stryker's current Enterprise Value is MXN1,980,505 Mil.
Stryker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN125,565 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stryker (MEX:SYK) has a EV-to-EBITDA of 15.77 as of Sep. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stryker. This is 39% below median its historical median of 25.81. Over the past decade, Stryker's EV-to-EBITDA has ranged from 16.20 to 37.99. According to the industry distribution chart, Stryker ranks #306 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 59.3%.
Is Stryker's EV-to-EBITDA too high?
Stryker's current EV-to-EBITDA of 15.77 is 39% below median its 10-year median of 25.81. Over the past 10 years, this metric has ranged from a low of 16.20 to a high of 37.99. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.93. Stryker's value of 15.77 is 13.2% above this industry median. Based on the distribution chart, Stryker ranks #306 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stryker has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stryker's EV-to-EBITDA compare to MDT and BSX?
According to the Medical Devices & Instruments industry distribution chart, Stryker ranks #306 out of 516 companies for EV-to-EBITDA. This places Stryker in the lower half of its industry. The industry median EV-to-EBITDA is 13.93. Stryker's value of 15.77 is 13.2% above this benchmark. Historically, Stryker's own EV-to-EBITDA has ranged from 16.20 to 37.99 over the past decade. While the company's 10-year median is 25.81 vs. the industry median of 13.93, Stryker has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stryker's current EV-to-EBITDA of 15.77 is 13.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Stryker. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stryker's current EV-to-EBITDA is 15.77, which is 39% below median its own 10-year median of 25.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stryker stock overvalued right now?
Based on GuruFocus' analysis, Stryker (MEX:SYK) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN7,233.90, compared to a current price of MXN4,770.00 — trading 34.1% below its estimated fair value. The current EV-to-EBITDA is 15.77, which is 39% below median its 10-year median of 25.81 and 13.2% above the Medical Devices & Instruments industry median of 13.93. Stryker's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Stryker (MEX:SYK), the current EV-to-EBITDA is 15.77 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stryker (MEX:SYK) Overvalued in 2026?
Based on GuruFocus' analysis, Stryker stock appears to be undervalued.
The current stock price of MXN4,770.00 is trading 34.1% below its estimated GF Value™ of MXN7,233.90.
GuruFocus considers Stryker to be Significantly Undervalued.
Key valuation signals for MEX:SYK:
EV-to-EBITDA: 15.77 (39% below median its 10-year median of 25.81)
GF Value™: MXN7,233.90 vs. price of MXN4,770.00 (34.1% below fair value)
Industry Position: 13.2% above the Medical Devices & Instruments median (#306 of 516)
No single metric tells the full story. See the MEX:SYK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
90GF Score
Get the complete analysis for MEX:SYK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SYK has been successfully added to your 
